LabCompass

Swapna Joshi

Medicine · Indiana University

OpenAlex
Glioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismAcute Myeloid Leukemia ResearchEpigenetics and DNA MethylationPancreatic and Hepatic Oncology Research

Publications

86

Citations

1,462

Est. group size

—

Recurring co-author estimate

Active years

20

Publishing since 2007

Research summary
AI-generated

Swapna Joshi studies blood cancers and other diseases at the level of individual cells and their DNA, with a focus on how patients respond to therapies for myelodysplastic syndromes (a group of bone marrow disorders) and acute myeloid leukemia. The work often uses single-cell profiling and DNA methylation analysis (chemical marks that switch genes on or off) to understand why drugs like azacitidine work or fail. Related projects extend to brain tumors, cell-based immunotherapies, and links between gut microbes and conditions such as autism and autoimmune lung disease.

Blood cancer therapy response (leukemia and MDS)DNA methylation and epigeneticsSingle-cell multi-omics profilingGut microbiome and diseaseCell-based immunotherapy (CAR-T, iPSC-derived cells)

Publication activity has been steady and generally growing over the past decade, peaking around 2022-2023 and averaging about seven papers per year over the last five years.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence
Publications per year over the last 10 years — averaging 7.2/year recently
2017: 6 publications172018: 6 publications182019: 2 publications192020: 7 publications202021: 6 publications212022: 9 publications222023: 11 publications11232024: 8 publications242025: 6 publications252026: 2 publications26
Recent publications
Publishes in
  • Neuro-Oncology×10
  • Blood×7
  • Cancer Research×4
  • Research Square×4
  • Experimental Hematology×3

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile